Mechanisms of drug toxicity and relevance to pharmaceutical development.
about
Using zebrafish to model erythroid lineage toxicity and regenerationNew surface radiolabeling schemes of super paramagnetic iron oxide nanoparticles (SPIONs) for biodistribution studiesThe concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.Relationships Between Pharmacovigilance, Molecular, Structural, and Pathway Data: Revealing Mechanisms for Immune-Mediated Drug-Induced Liver Injury.Effect of cocaine dependence on brain connections: clinical implications.Mechanism of quinine-dependent monoclonal antibody binding to platelet glycoprotein IIb/IIIa.Remote control of glucose homeostasis in vivo using photopharmacology.High Content Imaging and Analysis Enable Quantitative In Situ Assessment of CYP3A4 Using Cryopreserved Differentiated HepaRG Cells.Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters (CAGCs)Molecular mechanisms of the microsomal mixed function oxidases and biological and pathological implicationsMetabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactorConcordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targetsThe Safety Evaluation of Salvianolic Acid B and Ginsenoside Rg1 Combination on Mice.A Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity.Modeling Reactivity to Biological Macromolecules with a Deep Multitask Network.The influence of the carrier molecule on amoxicillin recognition by specific IgE in patients with immediate hypersensitivity reactions to betalactams.Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.The evolution of our understanding of endo-xenobiotic crosstalk and cytochrome P450 regulation and the therapeutic implications.Impact of biomarkers on clinical trial risk.Safety biomarkers in preclinical development: translational potential.Alginate Particles as Platform for Drug Delivery by the Oral Route: State-of-the-Art.Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis.The role for microRNAs in drug toxicity and in safety assessment.Adverse Outcome Pathways and Drug-Induced Liver Injury Testing.Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses.Development of a profiling strategy for metabolic mixtures by combining chromatography and mass spectrometry with cell-based GPCR signaling.Adverse Drug Reactions for Medicines Newly Approved in Japan from 1999 to 2013: Hypertension and Hypotension.Is the precautionary principle adaptable to emergency scenarios to speed up research, risking the individual informed consent?Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.Deep Learning to Predict the Formation of Quinone Species in Drug Metabolism.Humanizing the zebrafish liver shifts drug metabolic profiles and improves pharmacokinetics of CYP3A4 substrates.A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours.Target Safety Assessment: Strategies and Resources.Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury."Drugs on oxygen": an update and perspective on the role of cytochrome P450 testing in pharmacology.Glomerulonephritis-Induced Changes in Urinary and Kidney MicroRNA Profiles in Rats.Cardiovascular Safety in Drug Development: A Role for Endothelial Function Tests.Understanding P450-mediated Bio-transformations into Epoxide and Phenolic Metabolites.
P2860
Q27333250-76938248-0F1C-4CD8-94AC-130016851F59Q28834078-1208A613-98F9-45C4-8BCC-AA956568B495Q30854543-60E669B8-8DB1-4E86-9891-3A43A47B07F7Q30990061-997789D7-DF58-4628-B3B3-D10A347F778BQ31012723-9B5ECBAF-7919-4D48-8FFB-3C72483905B1Q33425721-582AE420-8115-4912-9BA8-4B46FA50CB93Q33670713-07C59189-5279-4445-82C0-144CC6D63B18Q34222455-8406D112-77FB-4C8B-B4E2-31F11D859668Q35006731-D8F99727-95C5-443F-916B-254D60E46822Q35024501-8BCF2F9B-94A5-40CD-A73D-B10B1D0D7A98Q35745230-8416874B-96C3-4446-B183-FAE88A7382AFQ36158922-EE4E8DD5-8236-4BCC-8C4C-5CF1858356C9Q36404214-A6A4F5C6-0BF4-454C-ACA0-5DF564DDD0EFQ36653948-65E5ED28-446D-4F77-8D71-B624166495D2Q37209287-E5808391-1306-4B57-9AD5-78F78291FFA3Q37330476-2BF8F4B1-B766-429A-A370-C6FF92A74979Q37564187-6784CBC3-8540-4025-AD97-844243521D0DQ38061448-4B657866-95DA-4999-86A6-F2DE6DB5E0D3Q38128592-A50AFC0D-EEA0-49B9-9E27-0AB78F1622BDQ38148601-0F284D74-2AFA-4DAD-A965-DB43EA92DE1DQ38148980-2F22187C-9151-4C46-AFEB-4A2DD74C6FB1Q38237646-50647455-0E49-4B6C-AF91-5A3C1C32174EQ38307244-DD7F56F5-A0C2-40E2-9340-66A7F121F1D5Q38367620-005621F2-15A9-4DE4-B398-0C3B26417198Q38539524-52DA58E3-56DD-4CEB-B225-7C978ADFA0C7Q38675826-019591E1-72FD-48B4-9E26-04C525428AD1Q38725134-07EF78EA-785B-4DD9-BE5C-DA1DE99DBEA4Q39323929-1821CC3B-02DA-44C5-88BA-29F4717FEB83Q41313679-A6E838A4-C8D8-4F57-AFD9-CD0A72652311Q42250875-49DA5B74-2CE5-42DA-9B12-6AF039C32287Q42709339-2FFA3157-F19F-44A5-A8CF-1201161B9E52Q46431115-08BFC704-62C4-4060-989E-C357B2633E8AQ46507025-417B8E5C-A558-4B8A-A5ED-8B0BB406F039Q48170991-6C612628-C614-4294-ACAA-70A74B3FE122Q48711048-6B2F3753-1B16-4566-ACA5-4A94C64DFC43Q49219661-1BF806DD-9FB2-4099-A89C-53448EC98657Q51557998-D5570CA1-FBBE-4965-BF06-6E106AB25571Q52868874-A5D22249-FD97-476B-B152-02E6D8C95FDCQ53139178-B193A415-1595-4A83-AAEE-CA15FADD2505Q53667728-BF9DACA6-6E1A-4A8F-9E26-F5641BA6BCB0
P2860
Mechanisms of drug toxicity and relevance to pharmaceutical development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanisms of drug toxicity and relevance to pharmaceutical development.
@en
Mechanisms of drug toxicity and relevance to pharmaceutical development.
@nl
type
label
Mechanisms of drug toxicity and relevance to pharmaceutical development.
@en
Mechanisms of drug toxicity and relevance to pharmaceutical development.
@nl
prefLabel
Mechanisms of drug toxicity and relevance to pharmaceutical development.
@en
Mechanisms of drug toxicity and relevance to pharmaceutical development.
@nl
P2860
P1476
Mechanisms of drug toxicity and relevance to pharmaceutical development.
@en
P2093
F Peter Guengerich
P2860
P356
10.2133/DMPK.DMPK-10-RV-062
P577
2010-10-22T00:00:00Z